Ascendiant lowered the firm’s price target on SurgePays (SURG) to $5 from $9.75 and keeps a Buy rating on the shares. The company reported weaker Q4 revenue but should see a growth rebound in 2026, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SURG: